Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Learning objective
- Common cold agents
- Respiratory syncytial virus (RSV)
- Global oscillation of RSV and flu prevalence
- Impact of RSV (1)
- Impact of RSV (2)
- Human RSV bronchiolitis
- Vaccine-enhanced disease
- RSV is a global child killer
- Long-term effects of early life infection
- Palivizumab for RMS prevention (1)
- Palivizumab for RMS prevention (2)
- Motavizumab for RMS prevention
- RSV in older adults
- Etiological role of RSV-ARI
- Congestive heart failure (CHF) & RSV
- RSV in elderly and high-risk adults
- RESCEU: COPD Cohort Study
- One-year survival after RSV vs. influenza
- RSV affects all ages
- Progress at last for RSV prevention!
- RSV prevention summary
- Nirsevimab for RSV prevention
- Vaccines for RSV
- Journey to RSV vaccines
- Efficacy and safety of Ad26.RSV.preF
- RSV prefusion F protein vaccine in adults
- Bivalent RSV prefusion F (preF) vaccine
- Bivalent RSV preF vaccine in pregnancy
- Vaccine trials
- mRNA based RSV preF vaccine
- RSV vaccine and mAb snapshot
- Prospects for prevention of RSV disease
- Thank you!
Topics Covered
- Respiratory syncytial virus (RSV)
- Antibody responses to RSV
- Palivizumab
- Motavizumab
- RSV in elderly and high-risk adults
- Nirsevimab
- RSV vaccines
- Ad26.RSV.preF
- Bivalent RSV preF vaccine
- mRNA based RSV preF vaccine
- RSV disease prevention
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Openshaw, P. (2024, April 30). Respiratory syncytial virus vaccination [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/QOJN7427.Export Citation (RIS)
Publication History
Financial Disclosures
- Peter Openshaw has been a member of scientific advisory committees and/or spoken at meetings organised by Janssen, Sanofi, Moderna, Seqirus, AstraZeneca and GSK.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:00
A warm welcome
to this Henry Stewart talk
on respiratory syncytial
virus vaccination.
It's a most exciting
time in the field.
For those of us who
have been working in
this area for many years,
we finally do have
things which are going to
make a huge difference.
So please stick with the talk
right through to the end.
0:21
Now on this first slide,
we talk about
learning objective,
we want to review the
recent data on vaccination
against RSV and its potential
impact on public health.
0:33
On this next slide,
you can see what
a lot of common cold
viruses that are
something like a couple of
hundred serologically
distinct viruses,
all of which crowd into
the respiratory space.
Maybe that's no surprise because
a really ideal way of
survival for a virus is
to infect the respiratory mucosa
and to pass to
other people either
by droplets or sprays or
aerosols or by direct
contact through surfaces.
For the virus which has
struggled to perpetuate
itself in some other
method of transmission,
what is better than
becoming a common cold?
RSV is one of
the most important viruses
in childhood in particular.
1:16
This is just a bit of
background detail
for those of you who
like beautiful colored images
of what viruses look like.
I think we used to think
of the virus as a bit of
an amorphous blob. When I did
my PhD on it in the 1980s,
I found various
amorphous blobs on EM.
But this new understanding
of the structure is
quite fascinating.
You can see some red elements
on this graphic which
are the fusion proteins.
The major surface glycoprotein
G probably is mostly
around this little tip
of this graphic not
being so well imaged.
But the virus attaches to the
cell and then fuses with it,
injecting the RNA which you can
see in the middle of
the graphic in blue.
A lot of the initial
gene transcription
is of the nonstructural
proteins which
essentially disable
the immune response
and allow repeated infections
with the same strain of virus.
The way the virus gets back in
repeatedly is a bit
different from things like,
influenza where
you see a lot of
evolution of the virus.
With RSV, it does evolve
but relatively slowly.
But its main weapon
against our immune
system is the ability
to disable it and to induce
a state of
immunological amnesia.